negative symptom

negative symptom

one of the deficit symptoms of schizophrenia that follow from diminished volition and executive function including inertia, anergia, lack of involvement with the environment, poverty of thought, social withdrawal, and blunted affect.

negative symptom

diminishing or absence of a characteristic of normal health as an indication of disease, such as the flat affect or mutism sometimes seen in schizophrenia. Compare positive symptom.

negative symptom

Any symptom involving loss of normal mental function, as seen in schizophrenia, psychosis, depression and other mental disorders.
 
Examples
Blunting or decreased range of affect; loss of will, pleasure, sense of purpose and social drives; inhibited fluency and content of speech, and range of motion; poverty of speech, movement and motivation; loss of interests in previously enjoyable activities.

negative symptom

Deficit symptom Psychiatry Any Sx involving loss of normal mental function, seen in schizophrenia, depression, and other mental disorders Examples Blunting of or ↓ range of affect, loss of will, pleasure, fluency, and content of speech, range of emotion, sense of purpose, social drives, poverty of speech, loss of interests. See Positive and Negative Symptom Scale, Schizophrenia. Cf Positive symptom.

neg·a·tive symp·tom

(neg'ă-tiv simp'tŏm)
One of the deficit symptoms of schizophrenia that follow from diminished volition and executive function including inertia, anergia, lack of involvement with the environment, poverty of thought, social withdrawal, and blunted affect.
References in periodicals archive ?
This becomes more disheartening against the backdrop that people with a DUP <1 year show substantially greater negative symptom reduction, especially when DUP is <9 months, compared with those with a DUP of >1 year.
But a significant decrease was seen in the negative symptom of alogia factor score (12).
Post hoc comparisons using the Bonferroni procedure indicated that individuals in Cluster 2, the most severe group with the poorest attention and memory function in our study, had the highest mean negative symptom score of 18.
Although as an acute schizophrenia trial, ITI-007-005 was not designed to look just at negative symptoms of schizophrenia, the investigators predefined a subgroup population analysis of patients who had prominent negative symptoms at baseline (defined as a score of 4 or more on at least three negative symptom items on the PANSS at baseline).
The analysis showed that Latuda treatment in the prominent negative symptom group was associated with significantly greater week six improvement compared to placebo on the PANSS-negative subscale score (-6.
Roche today announced that two phase III studies of its investigational medicine bitopertin (RG1678) in adults with persistent, predominant negative symptoms of schizophrenia failed to meet their primary endpoints, based on the negative symptoms factor score of the positive and negative symptom scale (PANSS).
Only schizophrenia patients with a score below 6 on the Positive and Negative Symptom Scale (PANSS) were included.
PHILADELPHIA, April 28, 2011 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced positive results from a signal-finding study of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules (CII) assessing its effect in a prospective examination of adults with negative symptom predominant schizophrenia.
Cariprazine at 3-6 mg/day outperformed placebo in all but the Marder negative symptom factor grouping, where a trend favoring the drug fell short of statistical significance.
Consistent with preliminary indications from the interim analysis and with the drug's pharmacological profile, ITI-007 at a dose of 60 mg significantly improved certain items on the negative symptom and general psychopathology subscales consistent with improved social function.
Additionally, results from this Phase 2b trial demonstrated that patients treated with EVP-6124 showed clinically meaningful and statistically significant effects in key secondary endpoints: improvement in clinical function (as assessed by the Schizophrenia Cognition Rating Scale (SCoRS)) and reduction of the negative symptoms of schizophrenia (as measured by the Negative Symptom Scale of the Positive and Negative Symptoms Scale (PANSS)).
In the study, these symptoms were assessed using the validated 16-item Negative Symptom Assessment scale (NSA-16).